Based on the TCGA-PRAD cohorts, we found that RFS was shorter among patients with high DDX49 expression than among patients with low DDX49 expression (Fig. 2A, p = 0.025); this was also confirmed in the MSKCC cohorts (Fig. 2B, p = 0.036). This evidence concerns the gene DDX49 and prostate adenocarcinoma.